UECKER DARRIN

CTO Darrin Uecker sold 45,000 shares across two days (45.0K shares) for $731,200.00 totaling blended average price of $16.25

Darrin Uecker, Chief Technology Officer of Pulse Biosciences, executed 2 separate sales totaling 45,000 shares for $731,200.00 on September 16-17, 2025, reducing his holdings by 13.7% to 284,406 shares. The sales occurred at a blended average price of $16.25, notably below the current price of $18.52, despite the stock trading 24.6% below its 52-week high of $24.56. The company remains unprofitable with a net loss of $-19,168,000.00 and zero revenue in its latest quarter, creating a context where large insider liquidations merit investor attention. The CTO's 3 prior same-ticker sales within days prior (September 11, 12, 15) suggest a pattern of accumulated liquidation activity, though near-term outcome measurement is not yet available.

CTO Darrin Uecker sold 75,000 shares at $14.96 avg for $1,121,750, reducing stake by 37.9% while company burns $19.2M annually.

Darrin Uecker, Chief Technology Officer of Pulse Biosciences, executed 3 separate sales totaling 75,000 shares for $1,121,750.00 on consecutive trading days (September 11–15, 2025). This represents a 37.9% reduction in his holdings from 197,872 shares to 122,872 shares. The company reported net income of $-19,168,000.00 and zero revenue in its latest quarter, indicating active operating losses and no current commercial revenue generation. The blended sale price of $14.96 compares to the current price of $15.74, placing the stock near intermediate-term lows and 35.9% below its 52-week high of $24.56. A substantial disposal by the CTO of a material fraction of his equity stake at depressed valuation relative to year-long trading range warrants examination of the transaction's context—whether driven by liquidity needs, loss of conviction in near-term performance, or other factors.